?. Zent, C. S. , and B. J. Smith, Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.87, issue.2, pp.211-217, 2012.
DOI : 10.1158/1078-0432.CCR-07-0815

?. Zenz, T. , and A. Benner, Chronic lymphocytic leukemia and treatment resistance in cancer: The role of the p53 pathway, Cell Cycle, vol.7, issue.24, pp.3810-3814, 2008.
DOI : 10.4161/cc.7.24.7245

?. Zhou, Y. , and H. Zhen, PI3K/AKT Mediated P53 Down-Regulation Participates in CpG DNA Inhibition of Spontaneous B Cell Apoptosis, Cellular & Molecular Immunology, vol.6, issue.3, pp.175-180, 2009.
DOI : 10.1038/cmi.2009.24

?. Ziegler-heitbrock, H. W. , and R. Schlag, Favorable response of early stage B CLL patients to treatment with IFN-alpha 2, Blood, vol.73, issue.6, pp.1426-1430, 1989.

?. Zupo, S. , and R. Massara, Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD, Blood, vol.95, issue.4, pp.1199-1206, 2000.

?. Zupo, S. , and E. Rugari, CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells, European Journal of Immunology, vol.23, issue.5, pp.1218-1222, 1994.
DOI : 10.1002/eji.1830240532

M. Chen, D. Carvalho-bittencourt, M. Feugier, P. Faure, G. Béné et al., Active Toll-like receptor-7 triggering of chronic lymphocytic leukemia B-cells by imiquimod, Leukemia & Lymphoma, vol.87, issue.4, pp.739-781, 2012.
DOI : 10.1038/leu.2009.195

M. Chen, M. Mohtize, M. Matteï, J. Villemot, C. Kohler et al., Reduced levels of both circulating CD4+CD25+CD127low/neg and CD4+CD8neg invariant natural killer regulatory T cells in stable heart transplant recipients, Clinical & Experimental Immunology, vol.87, issue.1, pp.104-116, 2011.
DOI : 10.4049/jimmunol.177.12.8338

M. Bittencourt, B1 cells expressing CXCR3 possibly involved in the control of cardiac allograft rejection could be monitored in peripheral blood Abstract 2nd European Congress of Immunology in Berlin, 2009.

C. Gricks and J. Gribben, Cytotoxic T Cell Reponses Against Immunoglobulin in Malignant and Normal B Cells: Implications for Tumor Immunity and Autoimmunity, Current Pharmaceutical Design, vol.9, issue.23, pp.1889-1903, 2003.
DOI : 10.2174/1381612033454333

D. Spaner, Y. Shi, and D. White, Immunomodulatory eff ects of

C. Grandjenette, A. Kennel, and G. Faure, Expression of functional toll-like receptors by B-chronic lymphocytic leukemia cells, Haematologica, vol.92, issue.9, pp.1279-1281, 2007.
DOI : 10.3324/haematol.10975

D. Rozkov-Á, L. Novotn-Á, and R. Pytl-Í-k, Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation, International Journal of Cancer, vol.105, issue.5, pp.1132-1143, 2010.
DOI : 10.1182/blood-2004-10-3873

P. Lenert, A. Hammadi, C. Billard, and A. Faussat, Classifi cation, mechanisms of action, and therapeutic [6] applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9 Stimulation of iNOS [7] expression and apoptosis resistance in B-cell chronic lymphocytic leukemia (CLL) cells through engagement of Toll-like receptor 7 (TLR-7) and NF-? B activation, Mediators Infl amm Nitric Oxide, vol.201019, pp.986596138-145, 2008.

M. Sch-Ö-n and M. Sch-Ö-n, Imiquimod: mode of action, Br J Dermatol, vol.157, pp.8-13, 2007.

R. Collins, L. Verschuer, and B. Harmon, Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro, British Journal of Haematology, vol.18, issue.2, pp.181-187, 2004.
DOI : 10.1038/bjc.1987.186

C. Pepper, A. Thomas, and T. Hoy, The vitamin D3 analog EB1089 [10] induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in Leuk Lymphoma Downloaded from informahealthcare, p.12

B. Francia-di-celle, P. Mariani, S. Riera, and L. , Release of interleukin-6 in cultured B-chronic [13] lymphocytic leukaemia cells is associated with both activation and cell death via apoptosis Interleukin-8 induces [14] the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion, Anticancer Res Blood, vol.1987, pp.3953-3959, 1996.

D. Spaner, Y. Shi, and D. White, A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia, Leukemia, vol.176, issue.1, pp.222-226, 2010.
DOI : 10.4049/jimmunol.176.6.3830

R. Bottrel, Y. Yang, and D. Levy, Th e immune response [11] modifi er imiquimod requires STAT-1 for induction of interferon, interferon-stimulated genes, and interleukin-6, Antimicrob Agents Chemother, vol.43, pp.856-861, 1999.

K. Megyeri, W. Au, and I. Rosztoczy, Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways., Molecular and Cellular Biology, vol.15, issue.4, pp.2207-2218, 1995.
DOI : 10.1128/MCB.15.4.2207

. La-leucémie-lymphoïde-chronique, faible immunogénicité des cellules leucémiques est une maladie de présentation hétérogène dont l'évolution est liée à certains facteurs pronostiques. L'immunochimiothérapie a permis de progresser dans le traitement de cette pathologie, mais l'identification de nouvelles cibles d'immunothérapie serait souhaitable. Dans ce contexte, la présence de TLR-7 et TLR-9 sur les cellules de LLC est une piste intéressante. L'objectif principal de cette étude était ainsi de préciser les effets in vitro de l'engagement de TLR-7 et TLR-9 sur les cellules tumorales par leur ligands respectifs Imiquimod R837 et ODN CpG M362. Ces effets ont été examinés sur des LLC classées en formes stables ou agressives et/ou selon leur statut mutationnel IgVH. Les cellules séparées de 40 patients ont été cultivées pendant trois jours, avec du milieu seul, de l'acétate phorbolmyristate (PMA)